Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Oct;17(10):PH75-80.
doi: 10.12659/msm.881965.

Molecular epidemical characteristics of Lamivudine resistance mutations of HBV in southern China

Si-Yue Li  1 , Li Qin, Lei Zhang, Xing-Bo Song, Yi Zhou, Juan Zhou, Xiao-Jun Lu, Ju Cao, Lan-Lan Wang, Jun Wang, Bin-Wu Ying
Affiliations

Molecular epidemical characteristics of Lamivudine resistance mutations of HBV in southern China

Si-Yue Li et al. Med Sci Monit. 2011 Oct.

Abstract

Background: Lamivudine (LMV), as the preferred oral drug for use in treatment of HBV, always results in development of resistance mutations after long-term treatment. In this study we investigated chronic hepatitis B (CHB) patients in southern China to determine whether different HBV genotypes affect the incidence of LMV resistance mutations.

Material/methods: The study recruited 185 CHB patients living in southern China. Enzyme-linked immunosorbent assay was used to test for HBV serological markers, and HBV DNA was quantified by real-time PCR. Sequencing was performed to detect HBV genotypes and mutations.

Results: There were 49.19% (91/185) CHB patients with HBV resistant to LMV. Only 2 genotypes were found: B and C; 62.16% (115/185) of patients were infected with genotype B HBV and 37.84% (70/185) of patients were infected with genotype C HBV. The incidence rate of LMV resistance was not significantly different between genotype B and C (49.57% vs. 48.57%, P>0.05). For the mean age and sex ratio, no significant difference was found. The pattern of rtM204I alone was predominantly observed (36.26%, 33/91), followed by rtM204V+rtL180M (23.08%, 21/91). The overall incidence rate of rtM204I mutation in genotype B (45.61%, 26/57) was more frequent than that in genotype C (20.59%, 7/34) (45.61% vs. 20.59%, P<0.05), but the incidence rate of other mutation patterns was not significantly different between genotypes B and C.

Conclusions: Our results emphasize that a LMV resistance test before treatment is of great importance in rational and optimal CHB therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution and frequency of age between two groups according gender.
See this image and copyright information in PMC

References

    1. WHO. Hepatitis B. [Accessed 16/9/2010]. http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/
    1. WHO. Introduction of Hepatitis B Vaccine into Childhood Immunization Services. Geneva: WHO; 2001.
    1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107. - PubMed
    1. Colacino JM, Staschke KA. The identification and development of antiviral agents for the treatment of chronic hepatitis B virus infection. Prog Drug Res. 1998;50:259–322. - PubMed
    1. Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, Vazquez R, Ocete E, Olea N, Salmeron J. Increased risk of autoimmune thyroid disease in hepatitis C vs. hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med. 1998;158:1445–48. - PubMed

Publication types